Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Cancer Causes Control. 2009 Nov 10;21(2):289–300. doi: 10.1007/s10552-009-9461-5

Table 2.

Associations between SNPs in DNA repair genes and prostate cancer risk, by race

Caucasians African-American

Cases Controls Cases Controls
Gene SNP Genotype N % N % OR 95% CI Permuted P* N % N % OR 95% CI Permuted P*

APEX1 rs1320150 AA 424 33.5 415 33.4 1.00 - 0.42 57 40.1 37 46.8 1.00 - 0.84
AG 612 48.4 615 49.5 0.97 0.82–1.16 65 45.8 33 41.8 1.43 0.77–2.66
GG 229 18.1 212 17.1 1.06 0.84–1.33 20 14.1 9 11.4 1.48 0.58–3.79
AG + GG 841 66.5 827 66.6 1.00 0.84–1.18 85 59.9 42 53.2 1.44 0.80–2.59

APEX1 rs2275007 GG 420 33.4 415 33.5 1.00 - 0.79 61 43.0 37 46.8 1.00 - 0.53
AG 608 48.3 614 49.5 0.98 0.82–1.17 62 43.7 31 39.2 1.40 0.75–2.62
AA 230 18.3 211 17.0 1.08 0.85–1.36 19 13.4 11 13.9 1.08 0.44–2.65
AG + AA 838 66.6 825 66.5 1.01 0.85–1.19 81 57.0 42 53.2 1.32 0.73–2.36

BRCA2 rs144848 TT 655 51.6 654 52.6 1.00 - 0.52 104 73.2 59 74.7 1.00 - 0.36
GT 498 39.4 500 40.2 0.99 0.84–1.17 36 25.4 18 22.8 0.98 0.49–1.95
GG 116 9.1 89 7.2 1.30 0.98–1.75 2 1.4 2 2.5 0.48 0.06–3.85
GT + GG 614 48.5 589 47.4 1.04 0.89–1.22 38 26.8 20 25.3 0.93 0.48–1.81

BRCA2 rs15869 AA 770 60.8 787 63.3 1.00 - 0.59 136 95.1 71 89.9 1.00 - 0.90
AC 439 34.7 398 32.0 1.13 0.95–1.33 7 4.9 7 8.9 0.62 0.20–1.91
CC 57 4.5 59 4.7 0.99 0.68–1.44 - - 1 1.3 - -
AC + CC 496 39.2 457 36.7 1.11 0.94–1.30 7 4.9 8 10.1 0.53 0.18–1.58

BRCA2 rs1801406 AA 635 50.5 563 45.2 1.00 - 0.22 79 54.5 46 58.3 1.00 - 0.53
AG 501 39.9 556 44.6 0.80 0.68–0.94 58 40.0 31 39.2 1.13 0.62–2.06
GG 121 9.6 127 10.2 0.84 0.64–1.11 8 5.5 2 2.5 3.34 0.65–17.12
AG + GG 622 49.5 683 54.8 0.81 0.69–0.95 66 45.5 33 41.7 1.25 0.70–2.25

BRCA2 rs543304 TT 821 65.1 839 67.6 1.00 - 0.65 98 68.5 44 55.7 1.00 - 0.72
CT 399 31.6 364 29.3 1.12 0.94–1.33 42 29.4 30 38.0 0.59 0.32–1.10
CC 41 3.3 38 3.1 1.11 0.70–1.74 3 2.1 5 6.3 0.27 0.06–1.21
CT + CC 440 34.9 402 32.4 1.12 0.95–1.32 45 31.5 35 44.3 0.54 0.30–0.99

ERCC2 (XPD) rs1052555 CC 591 46.9 565 45.4 1.00 - 0.47 110 76.4 60 76.0 1.00 - 0.31
CT 549 43.6 535 43.0 0.98 0.83–1.16 29 20.1 17 21.5 0.82 0.40–1.68
TT 119 9.5 144 11.6 0.79 0.60–1.03 5 3.5 2 2.5 1.56 0.27–8.86
CT + TT 668 53.1 679 54.6 0.94 0.80–1.10 34 23.6 19 24.0 0.90 0.45–1.76

ERCC2 (XPD) rs13181 TT 505 41.0 480 39.1 1.00 - 0.17 87 59.6 50 60.2 1.00 - 0.41
GT 575 46.6 571 46.5 0.96 0.81–1.13 48 32.9 28 33.7 0.85 0.46–1.57
GG 153 12.4 177 14.4 0.82 0.64–1.05 11 7.5 5 6.0 1.19 0.37–3.78
GT + GG 728 59.0 748 60.9 0.92 0.79–1.09 59 40.4 33 39.7 0.90 0.50–1.61

ERCC2 (XPD) rs1799793 GG 545 44.0 527 43.2 1.00 - 0.08 106 73.6 65 79.3 1.00 - 0.77
AG 575 46.4 528 43.2 1.05 0.89–1.25 31 21.5 15 18.3 1.28 0.62–2.64
AA 120 9.7 166 13.6 0.70 0.54–0.91 7 4.9 2 2.4 2.35 0.44–12.43
AG + AA 695 56.1 694 56.8 0.97 0.83–1.13 38 26.4 17 20.7 1.40 0.71–2.77

ERCC2 (XPD) rs238406 GG 365 29.0 383 30.9 1.00 - 0.24 112 77.8 65 80.2 1.00 - 0.14
GT 636 50.4 600 48.5 1.11 0.93–1.33 29 20.1 16 19.8 0.98 0.48–2.00
TT 260 20.6 255 20.6 1.07 0.86–1.34 3 2.1 0 0.0 - -
GT + TT 896 71.1 855 69.1 1.10 0.93–1.31 32 22.2 16 19.8 1.09 0.54–2.20

ERCC4 (XPF) rs1799801 TT 633 50.3 623 50.1 1.00 - 0.91 96 66.2 55 69.6 1.00 - 0.72
CT 521 41.4 521 41.9 0.98 0.84–1.16 46 31.7 23 29.1 1.27 0.67–2.40
CC 105 8.3 99 8.0 1.04 0.78–1.40 3 2.1 1 1.3 3.02 0.29–30.9
CT + CC 626 49.7 620 49.9 0.99 0.85–1.16 49 33.8 24 30.4 1.33 0.71–2.49

ERCC4 (XPF) rs1800067 GG 1025 84.0 1012 83.0 1.00 - 0.79 136 94.4 78 96.3 1.00 - 0.59
AG 183 15.0 202 16.6 0.89 0.72–1.11 8 5.6 3 3.7 2.12 0.52–8.54
AA 13 1.1 5 0.4 2.58 0.92–7.25 - - - - - -
AG + AA 196 16.1 207 17.0 0.93 0.75–1.16

MGMT rs12917 CC 949 75.9 916 74.1 1.00 - 0.87 106 72.1 60 74.1 1.00 - 0.68
CT 269 21.5 298 24.1 0.87 0.72–1.05 35 23.8 20 24.7 1.18 0.61–2.29
TT 32 2.6 23 1.9 1.34 0.78–2.31 6 4.1 1 1.2 2.75 0.30–25.41
CT + TT 301 24.1 321 26.0 0.91 0.75–1.09 41 27.9 21 25.9 1.26 0.66–2.40

MGMT rs2308321 AA 926 76.7 922 77.2 1.00 - 0.50 130 92.9 73 91.3 1.00 - 0.39
AG 267 22.1 256 21.4 1.04 0.86–1.26 10 7.1 7 8.8 0.82 0.29–2.32
GG 14 1.2 17 1.4 0.82 0.40–1.67 - - - - - -
AG + GG 281 23.3 273 22.8 1.02 0.85–1.24

MGMT rs2308327 AA 950 76.1 960 77.1 1.00 - 0.75 134 92.4 75 90.4 1.00 - 0.31
AG 276 22.1 266 21.4 1.05 0.87–1.27 11 7.6 8 9.6 0.74 0.27–2.00
GG 22 1.8 20 1.6 1.11 0.60–2.05 - - - - - -
AG + GG 298 23.9 286 23.0 1.05 0.87–1.26

MUTYH rs3219484 GG 1085 86.4 1070 85.7 1.00 - 0.77 140 97.9 75 94.9 1.00 - 0.77
AG 164 13.1 173 13.9 0.94 0.74–1.18 3 2.1 4 5.1 0.29 0.06–1.36
AA 7 0.6 5 0.4 1.39 0.44–4.41 - - - - - -
AG + AA 171 13.6 178 14.3 0.95 0.76–1.19

MUTYH rs9429072 AA 720 57.1 686 55.0 1.00 - 0.37 34 23.5 24 30.4 1.00 - 0.54
AG 455 36.1 485 38.9 0.89 0.76–1.05 71 49.0 32 40.5 1.39 0.69–2.79
GG 85 6.8 76 6.1 1.07 0.77–1.48 40 27.6 23 29.1 1.11 0.51–2.39
AG + GG 540 42.9 561 45.0 0.92 0.78–1.07 111 76.6 55 69.6 1.27 0.67–2.42

OGG1 rs3218997 CC 1126 91.4 1137 91.5 1.00 - 0.84 139 95.9 77 97.5 1.00 - 0.52
CT 106 8.6 106 8.5 1.01 0.76–1.34 6 4.1 2 2.5 1.82 0.34–9.78

XPC rs1126547 CC 969 76.8 938 75.4 1.00 - 0.33 109 75.7 61 77.2 1.00 - 0.53
CG 273 21.6 287 23.1 0.92 0.76–1.11 30 20.8 17 21.5 0.93 0.46–1.89
GG 20 1.6 19 1.5 1.01 0.54–1.91 5 3.5 1 1.3 1.92 0.21–17.34
CG + GG 293 23.2 306 24.6 0.93 0.77–1.11 35 24.3 18 22.8 0.99 0.50–1.97

XPC rs2228001 AA 457 36.4 461 36.9 1.00 - 0.66 70 47.6 36 43.4 1.00 - 0.23
AC 595 47.3 600 48.0 1.00 0.84–1.19 61 41.5 38 45.8 0.80 0.44–1.46
CC 205 16.3 190 15.2 1.09 0.86–1.38 16 10.9 9 10.8 1.04 0.40–2.69
AC + CC 800 63.6 790 63.2 1.02 0.87–1.20 77 52.4 47 56.6 0.85 0.48–1.49

XPC rs2733532 CC 461 36.5 467 37.6 1.00 - 0.74 72 50.0 39 47.6 1.00 - 0.41
CT 602 47.7 599 48.2 1.02 0.86–1.21 57 39.6 35 42.7 0.91 0.50–1.65
TT 199 15.8 176 14.2 1.14 0.90–1.46 15 10.4 8 9.8 1.19 0.45–3.20
CT + TT 801 63.5 775 62.4 1.05 0.89–1.23 72 50.0 43 52.4 0.96 0.54–1.69

XPC rs2733534 GG 340 27.6 311 25.4 1.00 - 0.39 58 40.0 39 47.6 1.00 - 0.66
CG 607 49.2 635 51.8 0.88 0.72–1.06 64 44.1 35 42.7 1.24 0.67–2.28
CC 286 23.2 279 22.8 0.94 0.75–1.18 23 15.9 8 9.8 1.88 0.74–4.79
CG + CC 893 72.4 914 74.6 0.90 0.75–1.07 87 60.0 43 52.4 1.36 0.77–2.42

XPC rs8516 TT 771 61.1 753 60.3 1.00 - 0.85 106 73.6 66 83.5 1.00 - 0.76
CT 425 33.7 436 34.9 0.95 0.81–1.13 38 26.4 13 16.5 1.73 0.83–3.60
CC 66 5.2 60 4.8 1.08 0.75–1.55 - - - - - -
CT + CC 491 38.9 496 39.7 0.97 0.83–1.14

XRCC1 rs1799782 CC 1098 88.1 1071 86.7 1.00 - 0.23 131 89.7 72 86.8 1.00 - 0.60
CT 143 11.5 158 12.8 0.88 0.69–1.12 15 10.3 9 10.8 0.97 0.38–2.46
TT 5 0.4 6 0.5 0.82 0.25–2.68 - - 2 2.4 - -
CT + TT 148 11.9 164 13.3 0.88 0.69–1.11 15 10.3 11 13.2 0.77 0.32–1.86

XRCC1 rs25487 GG 522 41.5 481 38.8 1.00 - 0.77 103 71.5 53 64.6 1.00 - 0.83
AG 576 45.8 590 47.6 0.90 0.76–1.07 37 25.7 27 33.0 0.67 0.36–1.25
AA 159 12.7 169 13.6 0.87 0.68–1.11 4 2.8 2 2.4 0.97 0.16–5.84
AG + AA 735 58.5 759 61.2 0.89 0.76–1.05 41 28.5 29 35.4 0.69 0.38–1.27

XRCC1 rs25489 GG 1120 90.0 1145 91.4 1.00 - 0.26 137 93.8 76 91.6 1.00 - 0.61
AG 121 9.7 106 8.5 1.17 0.87–1.53 9 6.2 7 8.4 0.59 0.20–1.76
AA 3 0.2 2 0.2 1.55 0.26–9.27 - - - - - -
AG + AA 124 10.0 108 8.6 1.17 0.89–1.54

XRCC1 rs2854509 CC 798 63.4 777 62.8 1.00 - 0.66 98 67.6 56 70.0 1.00 - 0.21
AC 406 32.3 400 32.3 0.99 0.83–1.17 39 26.9 23 28.8 1.09 0.57–2.08
AA 55 4.4 61 4.9 0.88 0.60–1.28 8 5.5 1 1.3 2.94 0.34–25.66
AC + AA 461 36.6 461 37.2 0.97 0.83–1.14 47 32.4 24 30.0 1.19 0.64–2.21

XRCC1 rs915927 AA 400 31.8 409 32.8 1.00 - 0.73 62 42.8 30 38.0 1.00 - 0.41
AG 622 49.4 618 49.6 1.03 0.86–1.23 54 37.2 38 48.1 0.79 0.42–1.50
GG 238 18.9 220 17.6 1.11 0.88–1.39 29 20.0 11 13.9 1.32 0.56–3.11
AG + GG 860 68.3 838 67.2 1.05 0.89–1.24 83 57.2 49 62.0 0.92 0.51–1.65

Total number of cases and controls in both Caucasians and African-Americans vary by SNPs due to missing genotype data.

ORs and 95% CI are adjusted for age at diagnosis (cases) and age at reference date (controls).

*

Permuted P-values are for the co-dominant models (2 degrees of freedom) and present the adjusted P-values for multiple comparisons using a permutation procedure (see statistical methods for details).